Results of API–AI based regimen in osteosarcoma adult patients included in the French OS2006/Sarcome‐09 study - Archive ouverte HAL
Article Dans Une Revue International Journal of Cancer Année : 2019

Results of API–AI based regimen in osteosarcoma adult patients included in the French OS2006/Sarcome‐09 study

Isabelle Ray-Coquard
Christophe Perrin
  • Fonction : Auteur
Antoine Italiano
Olivier Collard
  • Fonction : Auteur
Jessy Delaye
  • Fonction : Auteur
Jean-Yves Blay
Sophie Piperno‐neumann
Bob‐valéry Occean
  • Fonction : Auteur
Marie‐cécile Le Deley
  • Fonction : Auteur
Jean‐yves Blay

Résumé

In the OS2006 study, patients younger than 18 years were treated with a methotrexate-based regimen (MTX), patients older than 25 years with a doxorubicin-cisplatin-ifosfamide-based regimen (API-AI), whereas patients aged 18-25 years received either API-AI or MTX. We herein report the prespecified subgroup analysis of the outcome of 106 patients treated with API-AI. Preoperative chemotherapy combined three doxorubicin-ifosfamide-cisplatin (API) and two doxorubicin-ifosfamide (AI) courses. Postoperative chemotherapy was assigned by risk group: localised patients with a good histological response (<10% viable cells) received two AI and two cisplatin-ifosfamide (PI) courses; patients with synchronous metastases, poor histological response or unresectable primary received five cycles of etoposide-ifosfamide (EI). Of the 106 patients, 61 were randomised to receive or not zoledronate. Median age was 30 years (range 18-67), 66 (62%) patients were >25 years. The primary tumours were axial in 28 patients (26%), and 28 (26%) presented with metastases. Ninety-six patients (91%) had surgery, conservative in 82 (85%); 36 patients (38%, 95% CI 28-48%) were good responders. Toxicity was manageable, with no significant difference in severe acute toxicity between patients aged >25 years and those younger. With a median follow-up of 4.8 years, the 5-year event-free survival and overall survival rates were 46% (95% CI 36-56) and 57% (95% CI 47-67), respectively. The primary tumour size and initial metastases correlated with a higher risk of event. In these 106 osteosarcoma adult patients, API-AI proved feasible with no excess of toxicity, and favourable activity despite poor-prognosis factors.

Dates et versions

hal-02530602 , version 1 (03-04-2020)

Identifiants

Citer

Sophie Piperno-Neumann, Isabelle Ray-Coquard, Bob-Valéry Occean, Valérie Laurence, Didier Cupissol, et al.. Results of API–AI based regimen in osteosarcoma adult patients included in the French OS2006/Sarcome‐09 study. International Journal of Cancer, 2019, 146 (2), pp.413-423. ⟨10.1002/ijc.32526⟩. ⟨hal-02530602⟩
132 Consultations
0 Téléchargements

Altmetric

Partager

More